Day 3 (October 12, 2019)

09:45 – 09:52: Outcomes of Integrating Individualized Tobacco Cessation Counseling in a Lung Cancer Screening Program – John Pagteilan
09:52 – 09:59: Outcomes of Smoking Cessation Counseling in a Surgical Clinic – Nicholas Tingquist
09:59 – 10:06: CNS Metastasis as Exclusion Criteria in Clinical Trials Involving Extensive-Stage Small Cell Lung Cancer – Takefumi Komiya
10:06 – 10:16: Discussant: Smoking Cessation and Inclusivity in Clinical Trials – Ticiana Leal
10:16 – 10:26: Clinical-Radiomic Models Predict Overall Survival Among Non-Small Cell Lung Cancer Patients Treated with Immunotherapy – Ilke Tunali
10:26 – 10:33: Lung Cancer Screening in Patients with versus Without a Personal History of Cancer – Patricia Rivera
10:33 – 10:40: Low Dose CT Lung Screening in First Responders – Vershalee Shukla
10:40 – 10:47: Peritumoral and Intratumoral Radiomic Features Identify Aggressive Screen-Detected Early-Stage Lung Cancers – Jaileene Perez Morales
10:47 – 10:54: Multi-Planar Lung Cancer Measurements Provide Improved Accuracy in Clinical Staging – Erin M. Corsini
10:54 – 11:04: Discussant: Radiomics, Screening and Imaging – Sharyn Katz

A Unscripted Life: Using Improvisational Theater Techniques to Help Women In Medicine Claim Power, Collaborate and Communicate – Katie Watson

11:30 – 11:45: Novel Tumor Biomarkers and Tumor Immune Profiling – Kurt Schalper
11:45 – 12:00: Microbiome and Implications for Response to IO – Thomas Gajewski
12:00 – 12:15: Treatment of Oligometastatic Disease Denovo and at Progression with Driver Mutations, on IO or Neither – Puneeth Iyengar and Luda Bazhenova
12:15 – 12:30: Closing Remarks

09:45 – 09:52: Biomarkers of Autoimmune Toxicity in Metastatic SCLC Patients Receiving PD-1/PDL-1 Targeted Therapy – Apoorva Tangri
09:52 – 09:59: Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC) with Brain Metastases Treated with Pembrolizumab – Lova Sun
09:59 – 10:06: Multi-institutional Study of Pneumonitis after Treatment with Durvalumab and Chemoradiotherapy for Non-Small Cell Lung Cancer – Timothy Sita
10:06 – 10:13: Analysis of Patient Microbiome and its Correlation to Immunotherapy Response and Toxicity in Lung Cancer – Jun Zhang
10:13 – 10:23: Discussant: Predictors of IO Toxicity – Kristen Marrone
10:23 – 10:30: Impact of an EGFR-Lung Cancer Diagnosis on Quality of Life of Patients: Learnings from Project PRIORITY – Jill Feldman
10:30 – 10:37: Evaluating Racial Differences in KRAS-Mutant Non-Small Cell Lung Cancer – Jacqueline Aredo
10:37 – 10:44: Clinical Utility of ctDNA Driver Genomic Alterations (GA) Directing Targeted Therapy in Untreated Advanced NSCLC Patients – Benjamin Besse
10:44 – 10:51: Overall Survival in Patients with EGFRm+ NSCLC Receiving Sequential Afatinib and Osimertinib: An Update of the GioTag Study – Christoph Weinlinger
10:51 – 11:01: Discussant: Targeted Therapies: Partnerships, Inequities, and Best Therapies – Christine Lovly

08:15 – 08:20: Introduction
08:20 – 08:28: Rebiopsy after Progressive Disease, Pseudoprogression, Adjudication of Site Selection – Tim Murgu
08:28 – 08:35: Management of Malignant Effusion (TKIs and IO) – Carla Lamb
08:35 – 08:43: MPR Post Neo-adjuvant IO – Ignacio Wistuba
08:43 – 08:51: Diagnostic and Management Dilemmas in Synchronous NSCLC – Elizabeth David
08:51 – 08:59: Ablative Radiation Therapy for Operable Disease – Megan Daly
08:59 – 09:15: Panel Discussion

08:15 – 08:18: Introduction – Lecia Sequist
08:18 – 08:25: Treatment of New and Emerging Driver Mutations – Paul Paik
08:25 – 08:32: Updates in ALK – Caroline McCoach
08:32 – 08:39: Progression after First Line Osimertinib – Lecia Sequist
08:39 – 08:46: Clinical Trials in MPM – Hedy Lee Kindler
08:46 – 08:52: SCLC – Updates – Anna Farago
08:52 – 09:00: CNS Disease- Systemic Therapy as First Line – From a Radiation Oncology Perspective – Vinai Gondi
09:00 – 09:15: Panel Discussion